Robert Aiken, MD
Neurology · Summit, NJNPI 1851372981
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,600 of the $6,675 with a category attached, or 83.9%. Servier Pharmaceuticals LLC accounts for 92.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $6,089 and has fallen 96.3% since, to $228 in 2025.
Across 28 payments — averaging $238.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$6K
- Novocure Inc.$380
- Aucta Pharmaceuticals, Inc.$42
- Telix Pharmaceuticals$40
- Springworks Therapeutics, Inc.$23
- Medtronic$22
- plus $16 from 1 others
Across 29 payments — averaging $4294.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$80K
- Karyopharm Therapeutics Inc.$34K
- Merck$10K
What the payments were for
- Consulting fees$5,60084%
- Travel & lodging$3906%
- Food & beverage$68510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 8 | $6,151 |
| Novocure Inc. | 13 | $380 |
| Aucta Pharmaceuticals, Inc. | 3 | $42 |
| Telix Pharmaceuticals | 1 | $40 |
| Springworks Therapeutics, Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Caris MPI, Inc. | 1 | $16 |
How this compares
$6,675 in reported general payments places this provider in the 65th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GleostineLomustine | 14 | $15,733 |
| Levetiracetam | 27 | $785 |
| Dexamethasone | 35 | $547 |
| Ondansetron Hcl | 11 | $137 |
Paid to pharmacies, not to this prescriber.
Other neurology in Summit
- Marcie RabinSummit$387K
- Nicholas MetrusSummit$49K
- Seth StollerSummit$35K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Ashish KapoorBayonne$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.